According to a new report, published by KBV research, The Global Colorectal Cancer Screening Market size is expected to reach $22.2 billion by 2030, rising at a market growth of 4.8% CAGR during the forecast period.
The Colonoscopy segment is leading the Global Colorectal Cancer Screening Market by Type in 2022; thereby, achieving a market value of $15.8 billion by 2030. A charged coupled device (CCD) camera or a fiber optic camera mounted on a flexible tube passed through the anus is used to perform an endoscopic inspection of the large bowel and the distal portion of the small bowl. Colonoscopy enables precise diagnosis and therapy without the need for a major operation. A colonoscope can also be used to remove the polyps from the colon.
The Diagnostic Imaging Centres segment is exhibiting a CAGR of 5.2% during (2023 - 2030). The expansion of the segment is attributable to the growing awareness among patients regarding the advantages of early cancer detection, which has increased the number of tests conducted in these labs. The rising incidence of colorectal cancer screening through colonoscopies and the growing number of diagnostic centers conducting colonoscopy procedures across the globe are among the main factors driving segmental growth.
The North America region dominated the Global Colorectal Cancer Screening Market by Region in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $9.2 billion by 2030. The Europe region is anticipated to grow at a CAGR of 4.4% during (2023 - 2030). Additionally, The Asia Pacific region would register a CAGR of 5.7% during (2023 - 2030).
Full Report: https://www.kbvresearch.com/colorectal-cancer-screening-market/
The market research report has exhaustive quantitative insights providing a clear picture of the market potential in various segments across the globe with country wise analysis in each discussed region. The key impacting factors of the market have been discussed in the report with the elaborated company profiles of Novigenix SA, Eiken Chemical Co., Ltd., Clinical Genomics Pathology, Inc., Exact Sciences Corporation, Epigenomics AG, BioMerieux S.A., Olympus Corporation, Sysmex Corporation, Fujifilm Holdings Corporation, and Siemens Healthineers AG (Siemens AG).
By Type
By End-user
By Geography
Companies Profiled
Unique Offerings 
